In silico repurposing of midostaurin as a therapeutic candidate for head and neck cancer via targeting SPARC/MMP9/CD44 Cancer-Associated Fibroblasts (CAFs) oncogenic signature

Taipei Medical University Institutional Repository > 教師升等著作 > 教師升等送審著作 > 112 > Item 987654321/64820

請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/64820

題名:	In silico repurposing of midostaurin as a therapeutic candidate for head and neck cancer via targeting SPARC/MMP9/CD44 Cancer-Associated Fibroblasts (CAFs) oncogenic signature
作者:	劉明哲 Lin, Kuan-Chou;Wu, Chia-Che;Mokgautsi, Ntlotlang;Lawal, Bashir;Wu, Ching-Zong;Wu, Alexander Th;Shen, Yung-Kang;Liu, Ming-Che
貢獻者:	牙體技術學系
關鍵詞:	Head and neck squamous cancers (HNSCC);cancer-associated fibroblasts (CAFs);drug resistance;midostaurin;molecular docking
日期:	2023-03
上傳時間:	2024-12-04 14:04:59 (UTC+8)
摘要:	Head and neck squamous carcinoma (HNSCC) affects more than half a million individuals and ranks the ninth leading cause of death globally each year. Many patients develop treatment resistance leading to poor clinical outcomes. The poor treatment responses are in part due to the heterogeneity of HNSCC tumor and tumor microenvironment (TME). The interaction of tumor cells with their TME has been studied vigorously in recent years because of their pivotal roles in tumorigenesis and determining the treatment response. Cancer-associated fibroblasts (CAFs) are one of the most abundant tumor-infiltrating cells; which have been shown to associate with the aggressive behavior of HNSCC. Hence; targeting and disrupting the tumor-CAFs interactions represents a rational therapeutic approach. To develop targeted therapeutic drugs against CAFs; the identification of CAF-associated gene signature is essential. Here; we analyzed multiple sequencing databases including microarrays and single-cell RNA-sequencing databases and identified SPARC/MMP9/CD44 as HNSCC targetable gene signatures encompassing cancer-associated fibroblasts (CAFs). We found SPARC/MMP9CD44 signature was highly expressed in HNSC tissues compared to adjacent normal tissues. Increased SPARC/MMP9/CD44 signature levels strongly correlated with tumor-infiltrating CAFs; suggesting the functional importance of this signature for HNSCC-CAFs interaction and progression. Subsequently; we utilized a genomics approach and identified midostaurin as the top-ranking drug candidate for targeting SPARC/MMP9/CD44 signature. For validation; we performed molecular docking of midostaurin in complex with SPARC/MMP9/CD44 and demonstrated midostaurin's high binding affinities compared to their respective standard inhibitors. In summary; our study provided a rapid genomics approach for identifying targetable gene signature and drug candidate for HNSCC.
關聯:	American journal of cancer research; 13(3); 1004–1025.
描述:	【112-2 升等】臺北醫學大學教師升等專門著作職別：專任送審等級：教授著作送審
附註:	代表著作名稱：《In silico repurposing of midostaurin as a therapeutic candidate for head and neck cancer via targeting SPARC/MMP9/CD44 Cancer-Associated Fibroblasts (CAFs) oncogenic signature》 AJCR Copyright ? 2023.
資料類型:	article
顯示於類別:	[教師升等送審著作] 112 [牙體技術學系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	49	檢視/開啟

在TMUIR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....